NO941821L - Inhibitorer av cellereguleringsfaktorer samt metoder for forebyggelse eller reduksjon av arrdannelse - Google Patents

Inhibitorer av cellereguleringsfaktorer samt metoder for forebyggelse eller reduksjon av arrdannelse

Info

Publication number: NO941821L
Authority: NO; Norway
Prior art keywords: decorin; methods; cell regulatory; regulatory factor; protein
Prior art date: 1991-11-14

Application number

NO941821A

Other languages

English (en)

Norwegian (no)

Other versions

NO941821D0 (no

Inventor

Erkki I Ruoslahti

Michael T Longaker

David J Whitby

John R Harper

Michael D Pierschbacher

Wayne A Border

Original Assignee

Jolla Cancer Res Found

Univ California

Univ Utah

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-11-14

Filing date

1994-05-13

Publication date

1994-07-14

1994-05-13 Application filed by Jolla Cancer Res Found, Univ California, Univ Utah filed Critical Jolla Cancer Res Found

1994-05-13 Publication of NO941821D0 publication Critical patent/NO941821D0/no

1994-07-14 Publication of NO941821L publication Critical patent/NO941821L/no

Links

238000000034 method Methods 0.000 title abstract 7
230000002265 prevention Effects 0.000 title abstract 2
230000037390 scarring Effects 0.000 title abstract 2
230000009134 cell regulation Effects 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
102000004237 Decorin Human genes 0.000 abstract 6
108090000738 Decorin Proteins 0.000 abstract 6
210000004027 cell Anatomy 0.000 abstract 6
102000004169 proteins and genes Human genes 0.000 abstract 4
230000001105 regulatory effect Effects 0.000 abstract 4
108090000623 proteins and genes Proteins 0.000 abstract 3
208000027418 Wounds and injury Diseases 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
229920001184 polypeptide Polymers 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
102000037983 regulatory factors Human genes 0.000 abstract 2
108091008025 regulatory factors Proteins 0.000 abstract 2
229920002683 Glycosaminoglycan Polymers 0.000 abstract 1
108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 abstract 1
206010072170 Skin wound Diseases 0.000 abstract 1
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
206010052428 Wound Diseases 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
230000006378 damage Effects 0.000 abstract 1
238000001514 detection method Methods 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
108091006104 gene-regulatory proteins Proteins 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
210000004901 leucine-rich repeat Anatomy 0.000 abstract 1
230000001575 pathological effect Effects 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
238000000746 purification Methods 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
238000011477 surgical intervention Methods 0.000 abstract 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Zoology (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Electroluminescent Light Sources (AREA)

NO941821A 1991-11-14 1994-05-13 Inhibitorer av cellereguleringsfaktorer samt metoder for forebyggelse eller reduksjon av arrdannelse NO941821L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US79219291A	1991-11-14	1991-11-14
US88234592A	1992-05-13	1992-05-13
PCT/US1992/009871 WO1993009800A1 (en)	1991-11-14	1992-11-13	Inhibitors of cell regulatory factors and methods for preventing or reducing scarring

Publications (2)

Publication Number	Publication Date
NO941821D0 NO941821D0 (no)	1994-05-13
NO941821L true NO941821L (no)	1994-07-14

Family

ID=27121246

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO941821A NO941821L (no)	1991-11-14	1994-05-13	Inhibitorer av cellereguleringsfaktorer samt metoder for forebyggelse eller reduksjon av arrdannelse

Country Status (10)

Country	Link
EP (2)	EP0667784B1 (de)
JP (1)	JPH07504886A (de)
AT (1)	ATE233568T1 (de)
AU (1)	AU673506B2 (de)
CA (1)	CA2123418A1 (de)
DE (1)	DE69232946T2 (de)
ES (1)	ES2188585T3 (de)
FI (1)	FI942244A7 (de)
NO (1)	NO941821L (de)
WO (1)	WO1993009800A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5834444A (en) *	1991-07-03	1998-11-10	Hyal Pharmaceutical Corporation	Hyaluronic acid and salts thereof inhibit arterial restenosis
US6395494B1 (en)	1993-05-13	2002-05-28	Neorx Corporation	Method to determine TGF-β
WO1994020512A2 (en) *	1993-03-01	1994-09-15	Glycan Pharmaceuticals, Inc.	Analogs for specific oligosaccharide-protein interactions and uses therefor
JPH09505057A (ja) *	1993-11-19	1997-05-20	ザ・ユニバーシティ・オブ・シドニー	白内障を予防または制御するための方法
GB2304045A (en) †	1995-08-04	1997-03-12	Univ Manchester	Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
US6117911A (en)	1997-04-11	2000-09-12	Neorx Corporation	Compounds and therapies for the prevention of vascular and non-vascular pathologies
AU2008200019B2 (en) *	1999-01-05	2009-10-08	American National Red Cross	Methods for treating conditions associated with the accumulation of excess extracellular matrix
US7763580B2 (en)	1999-01-05	2010-07-27	University Of Utah Research Foundation	Methods for treating conditions associated with the accumulation of excess extracellular matrix
AU771635B2 (en) *	1999-01-05	2004-04-01	American National Red Cross, The	Methods for treating conditions associated with the accumulation of excess extracellular matrix
WO2002068647A2 (en) *	2001-01-16	2002-09-06	Curagen Corporation	Proteins, polynucleotides encoding them and methods of using the same
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
CN1506042A (zh)	2002-12-11	2004-06-23	苏加璐	使用来自胎儿细胞和组织的化合物改善皮肤状况的方法和组合物
GB0309064D0 (en)	2003-04-22	2003-05-28	Univ Manchester	Modified peptides and their uses
EP1740615B1 (de)	2004-03-31	2014-11-05	Genentech, Inc.	Humanisierte anti-tgf-beta-antikörper
EP2862867A3 (de)	2005-10-25	2015-08-05	The Johns Hopkins University	Verfahren und Zusammensetzungen zur Behandlung des Marfan-Syndroms und assoziierter Erkrankungen
US8454952B2 (en)	2006-03-13	2013-06-04	The Johns Hopkins University	Augmentation of endothelial thromboresistance
MX2009003518A (es)	2006-10-03	2009-08-25	Genzyme Corp	Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
WO2009135135A2 (en) *	2008-05-01	2009-11-05	Chia Soo	Fibromodulin formulation for reducing corneal scarring
KR100983182B1 (ko)	2009-08-14	2010-09-20	(주)엔솔테크	신규 펩타이드 및 그 용도
CN103429732B (zh)	2010-12-27	2015-09-16	Lsip基金运营联合公司	iPS细胞及其制造方法
EP3456837A3 (de) *	2011-03-14	2019-04-24	Catalent Pharma Solutions, LLC	Decorinzusammensetzungen und verwendung davon
US20140308275A1 (en)	2011-07-27	2014-10-16	Inserm (Institut National De La Sante Et De La Recherche Medicale	Methods for diagnosing and treating myhre syndrome
AU2011379972B2 (en)	2011-10-26	2016-05-12	Seattle Children's Research Institute	Cysteamine in the treatment of fibrotic disease
ES2897740T3 (es)	2011-12-28	2022-03-02	Kyoto Prefectural Public Univ Corp	Normalización del cultivo de células endoteliales de la córnea
EP2989208A4 (de)	2013-04-22	2016-12-07	Catalent Pharma Solutions Llc	Decorinzusammensetzungen für die veterinärmedizin und verwendung davon
CA2927898C (en)	2013-10-31	2021-11-16	Kyoto Prefectural Public University Corporation	Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
WO2016187312A1 (en)	2015-05-18	2016-11-24	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Methods and compositions for treating an alphavirus infection
JP2026504137A (ja) *	2023-01-27	2026-02-03	アロア・バイオサージェリー・リミテッド	組織虚血並びに関連した疾患及び容態を処置するための方法及び薬剤
WO2024158300A1 (en) *	2023-01-27	2024-08-02	Aroa Biosurgery Limited	Methods and agents for treating soft tissue inflammation and associated diseases and conditions
AU2024212702A1 (en) *	2023-01-27	2025-08-21	Aroa Biosurgery Limited	Methods and agents for treating respiratory inflammation and associated diseases and conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2887325B2 (ja) *	1988-06-28	1999-04-26	ラホヤキャンサーリサーチファウンデーション	デコリンによる細胞増殖の抑制
AU628910B2 (en) *	1988-12-20	1992-09-24	La Jolla Cancer Research Foundation	Polypeptide-polymer conjugates active in wound healing
WO1991010727A1 (en) *	1990-01-22	1991-07-25	La Jolla Cancer Research Foundation	Inhibitors of cell regulatory factors
GB9106678D0 (en) *	1991-03-28	1991-05-15	Ferguson Mark W J	Wound healing

1992
- 1992-11-13 WO PCT/US1992/009871 patent/WO1993009800A1/en not_active Ceased
- 1992-11-13 EP EP92925260A patent/EP0667784B1/de not_active Expired - Lifetime
- 1992-11-13 AU AU31385/93A patent/AU673506B2/en not_active Ceased
- 1992-11-13 AT AT92925260T patent/ATE233568T1/de not_active IP Right Cessation
- 1992-11-13 DE DE69232946T patent/DE69232946T2/de not_active Expired - Fee Related
- 1992-11-13 JP JP5509458A patent/JPH07504886A/ja active Pending
- 1992-11-13 ES ES92925260T patent/ES2188585T3/es not_active Expired - Lifetime
- 1992-11-13 CA CA002123418A patent/CA2123418A1/en not_active Abandoned
- 1992-11-13 EP EP02010251A patent/EP1230929A1/de not_active Withdrawn
1994
- 1994-05-13 FI FI942244A patent/FI942244A7/fi not_active Application Discontinuation
- 1994-05-13 NO NO941821A patent/NO941821L/no unknown

Also Published As

Publication number	Publication date
FI942244A7 (fi)	1994-07-06
WO1993009800A1 (en)	1993-05-27
JPH07504886A (ja)	1995-06-01
FI942244A0 (fi)	1994-05-13
EP0667784B1 (de)	2003-03-05
AU3138593A (en)	1993-06-15
DE69232946T2 (de)	2003-12-18
NO941821D0 (no)	1994-05-13
EP1230929A1 (de)	2002-08-14
DE69232946D1 (de)	2003-04-10
AU673506B2 (en)	1996-11-14
CA2123418A1 (en)	1993-05-27
ATE233568T1 (de)	2003-03-15
EP0667784A1 (de)	1995-08-23
ES2188585T3 (es)	2003-07-01

Publication	Publication Date	Title
NO941821L (no)	1994-07-14	Inhibitorer av cellereguleringsfaktorer samt metoder for forebyggelse eller reduksjon av arrdannelse
Klagsbrun et al.	1980	Purification of a cartilage-derived growth factor.
AU2987695A (en)	1996-02-16	Interruption of binding of mdm2 and p53 protein and therapeutic application thereof
CA1223198A (en)	1987-06-23	Repair of tissue in animals
HUP9904023A2 (hu)	2000-03-28	Leptin antagonisták alkalmazása inzulin rezisztencia kezelésére II. típusú cukorbajban
DE60037800D1 (de)	2008-03-06	Stereoselektive antifibrillogene peptide
BR8901711A (pt)	1989-11-21	Aperfeicoamento no processo para a polimerizacao em leito fluido de alfaolefinas
ATE186219T1 (de)	1999-11-15	Kombination von antihormonale und bindende moleküle zur krebsbehandlung
DE69027865D1 (de)	1996-08-22	ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
RU95106651A (ru)	1996-12-27	Аналоги дзе-тур динорфина и способ лечения толерантных состояний у пациента
HUP0000492A1 (hu)	2000-05-28	N-(Aril/heteroaril-acetil)-aminosav-észterek, azokat tartalmazó gyógyászati készítmények, valamint módszerek béta-amiloid fehérje képződése és felszabadulása gátlására e vegyületek felhasználásával
FI940375A0 (fi)	1994-01-26	Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
DE69838544D1 (de)	2007-11-22	Isolierung von gewebspezifischen peptidliganden und ihre verwendung zur ausrichtung von pharmazeutika auf zielorgane
DE69804839D1 (de)	2002-05-16	Cd8 als inhibitor des zellulären immunsystems
ATE286974T1 (de)	2005-01-15	Therapeutische domänen des von willebrand-faktor
NO943654L (no)	1994-12-05	Decorinfragmenter og fremgangsmåter for inhibering av celleregulerende faktorer
EP0319315A3 (de)	1990-05-23	Von Willebrand-Faktor, welcher den Faktor VIII verbindet
HU9503593D0 (en)	1996-02-28	Factor vii-derived peptides
ATE356145T1 (de)	2007-03-15	Polypeptide zur regenerierung des nervensystems
NO933742L (no)	1993-10-18	Humant, benavledet, insulinlignende vekstfaktorbindingsprotein
Karelin et al.	1999	Fragments of functional proteins: role in endocrine regulation
DE69229436D1 (de)	1999-07-22	Verwendung von somatostatinanalogen zur behandlung von melanomen
WO1997014966B1 (en)	1997-06-05	Method of activating a novel ligand regulatory pathway
GENNICK et al.	1987	Characterization of the subunit structure of the thyrotropin receptor in the FRTL-5 rat thyroid cell line
DE69712182D1 (de)	2002-05-29	Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises